Company Information

    Pear Therapeutics was founded on January 2013. The company is based in Boston, MA, USA . The number of employees in Pear Therapeutics is less than 250. Pear therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Pear Therapeutics has received 6 rounds of venture funding. The total funding amount is around $234M. Last venture funding round was $20M, announced on March, 2021.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Pear Therapeutics - Blog

                          • Pear Therapeutics to Participate in Evercore ISI Fourth Annual HealthCONx Conference

                          • BOSTON, November 23, 2021 – Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced management will participate in the Evercore ISI Fourth Annual HealthCONx Conference on Wednesday, December 1, 2021. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside… Read moreThe post Pear Therapeutics to Participate in Evercore ISI Fourth Annual HealthCONx Conference appeared first on Pear Therapeutics.
                          • Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use Disorder

                          • BOSTON, November 22, 2021 – Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its reSET-A™ PDT product candidate designed for the treatment of alcohol use disorder… Read moreThe post Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutic Candidate to Treat Alcohol Use Disorder appeared first on Pear Therapeutics.
                          • Pear Therapeutics Provides 2021 Business Update and Reaffirms Full Year 2021 Revenue Guidance

                          • BOSTON – November 15, 2021 – Pear Therapeutics, Inc. (“Pear”), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today provides an update on significant progress in its commercialization, pipeline, and platform strategy prior to the expected closing of its business combination with Thimble Point Acquisition… Read moreThe post Pear Therapeutics Provides 2021 Business Update and Reaffirms Full Year 2021 Revenue Guidance appeared first on Pear Therapeutics.
                          • Thimble Point and Pear Therapeutics Announce Additional $50 million in Committed Capital to Fund Business Plan

                          • Increases minimum gross proceeds from PIPE and Sponsor to $175 million Removes minimum cash as a condition to the closing of the business combination PIPE Investors have agreed to lock-up 82.4% of the PIPE shares  BOSTON – November 15, 2021 – Today, Thimble Point Acquisition Corp, Inc. (NASDAQ: THMA) (“Thimble… Read moreThe post Thimble Point and Pear Therapeutics Announce Additional $50 million in Committed Capital to Fund Business Plan appeared first on Pear Therapeutics.
                          • Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the November 2021 MassHealth Drug List Summary Update and MassHealth Non-Drug Product List

                          • Pear’s prescription digital therapeutics (PDTs), reSET® and reSET-O®, are included on the November 2021 MassHealth Drug List Summary Update and MassHealth Non-Drug Product List, effective November 1, 2021 MassHealth is now covering reSET and reSET-O for the treatment of substance use disorder and opioid use disorder, respectively, giving Massachusetts Medicaid… Read moreThe post Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the November 2021 MassHealth Drug List Summary Update and MassHealth Non-Drug Product List appeared first on Pear Therapeutics.
                          • Pear Therapeutics to Participate in the BTIG Digital Health Forum

                          • BOSTON, November 8, 2021 – Pear Therapeutics, Inc., the leader in developing and commercializing prescription digital therapeutics (PDTs) to treat serious disease, today announced management’s participation in the virtual BTIG Digital Health Forum being held on Monday, November 15. Corey McCann, M.D., Ph.D., President and CEO, will participate in a… Read moreThe post Pear Therapeutics to Participate in the BTIG Digital Health Forum appeared first on Pear Therapeutics.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *